Achillion Pharmaceuticals Appoints Dr. David Apelian Chief Medical Officer

New Haven, Conn. based Achillion Pharmaceuticals, a biopharmaceutical company currently focused on developing treatment for hepatitis C, has appointed David Apelian, MD, as its chief medical officer.

Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.

He will head the clinical development of Achillion's hepatitis C treatments.

More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast